Acorda Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acorda Therapeutics generated cash of -$13,984,000, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$14,060,000.
Cash Flow
| 2014 | 75.02M | -293.82M | 352.93M |
|---|---|---|---|
| 2015 | 38.48M | -85.23M | 17.78M |
| 2016 | 35.34M | -73.78M | 45.93M |
| 2017 | 96.5M | -10.71M | 61.51M |
| 2018 | 150.79M | -176.86M | 12.79M |
| 2019 | -128.16M | -505K | -60.55M |
| 2020 | -61.00M | 59.36M | -1.66M |
| 2021 | -41.34M | 73.77M | -69.65M |
| 2022 | -20.92M | -136K | 0 |
| 2023 | -13.98M | -264K | 0 |
ACOR Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 44.42M | 65.22M | 102.89M | 105.19M | 294.35M | 308.03M | 158.53M | 153.20M | 182.17M | 48.03M |
Operating activities | ||||||||||
Net income | -252.85M | -65.91M | -103.95M | -99.59M | -272.96M | 33.68M | -223.35M | -35.60M | 11.05M | 17.67M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 31.66M | 32.80M | 33.95M | 41.29M | 34.57M | 11.47M | 23.23M | 21.58M | 15.01M | 8.47M |
Stock-based compensation expense | 478K | 1.49M | 2.99M | 8.1M | 14.25M | 21.25M | 32.81M | 36.38M | 33.46M | 29.43M |
| Deferred income tax benefit | 478K | 1.49M | 2.99M | 8.1M | 14.25M | 21.25M | 32.81M | 36.38M | 33.46M | 29.43M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -3.43M | 2.58M | 3.19M | 1.89M | 1.34M | 57.97M | -29.11M | -19.96M | 744K | -1.42M |
Inventories | -3.40M | 5.79M | 7.86M | -3.45M | 3.79M | 8.44M | 5.50M | -6.66M | -9.63M | -665K |
Accounts payable | 884K | -7.35M | 1.10M | -8.97M | -60.56M | -3.48M | -3.57M | 37.62M | -825K | 13.18M |
Cash generated by operating activities | -13.98M | -20.92M | -41.34M | -61.00M | -128.16M | 150.79M | 96.5M | 35.34M | 38.48M | 75.02M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -226.58M | -249.10M | 0 | -40.21M | -434.67M | -580.38M |
Investments In Property Plant And Equipment | -264K | -136K | -191K | -4.39M | -90.42M | -33.91M | -14.37M | -273.53M | -7.06M | -483.93M |
Acquisitions Net | 0 | 0 | 73.96M | 0 | -89.92M | 587K | 0 | -267.34M | 1.14M | 478.85M |
Cash generated by investing activities | -264K | -136K | 73.77M | 59.36M | -505K | -176.86M | -10.71M | -73.78M | -85.23M | -293.82M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 24K | 15.19M | 10.47M | 75.52M | 18.09M | 16.01M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | -63.92M | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -91K | -1.74M | -60K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -69.65M | -597K | 0 | -657K | 0 | 0 | 0 | 0 |
Cash used in financing activities | 0 | 0 | -69.65M | -1.66M | -60.55M | 12.79M | 61.51M | 45.93M | 17.78M | 352.93M |
Net Change In Cash | -14.06M | -20.54M | -37.67M | -2.29M | -189.16M | -13.68M | 148.53M | 5.33M | -28.96M | 134.13M |
Cash at end of period | 30.36M | 44.67M | 65.22M | 102.89M | 105.19M | 294.35M | 307.06M | 158.53M | 153.20M | 182.17M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |